DK0777659T3 - Morpholinderivater og deres anvendelse som terapeutiske midler - Google Patents

Morpholinderivater og deres anvendelse som terapeutiske midler

Info

Publication number: DK0777659T3
Authority: DK; Denmark
Prior art keywords: 4alkyl; pct; hydrogen; 4alkoxy; hydroxy
Prior art date: 1994-08-15

Application number

DK95927862T

Other languages

English (en)

Inventor

Christopher John Swain

Timothy Harrison

Andrew Pate Owens

Original Assignee

Merck Sharp & Dohme

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-08-15

Filing date

1995-08-07

Publication date

2001-09-03

1994-08-15 Priority claimed from GB9416427A external-priority patent/GB9416427D0/en

1995-05-11 Priority claimed from GBGB9509605.3A external-priority patent/GB9509605D0/en

1995-08-07 Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme

2001-09-03 Application granted granted Critical

2001-09-03 Publication of DK0777659T3 publication Critical patent/DK0777659T3/da

Links

239000003814 drug Substances 0.000 title 1
150000002780 morpholines Chemical class 0.000 title 1
229940124597 therapeutic agent Drugs 0.000 title 1
229910052739 hydrogen Inorganic materials 0.000 abstract 4
239000001257 hydrogen Substances 0.000 abstract 4
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 2
125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
229910052760 oxygen Inorganic materials 0.000 abstract 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
125000006413 ring segment Chemical group 0.000 abstract 2
229910052717 sulfur Inorganic materials 0.000 abstract 2
241000689227 Cora <basidiomycete fungus> Species 0.000 abstract 1
206010061218 Inflammation Diseases 0.000 abstract 1
208000019695 Migraine disease Diseases 0.000 abstract 1
208000002193 Pain Diseases 0.000 abstract 1
206010036376 Postherpetic Neuralgia Diseases 0.000 abstract 1
206010047700 Vomiting Diseases 0.000 abstract 1
125000003118 aryl group Chemical group 0.000 abstract 1
125000004432 carbon atom Chemical group C* 0.000 abstract 1
125000004122 cyclic group Chemical group 0.000 abstract 1
125000005842 heteroatom Chemical group 0.000 abstract 1
125000000623 heterocyclic group Chemical group 0.000 abstract 1
125000002883 imidazolyl group Chemical group 0.000 abstract 1
230000004054 inflammatory process Effects 0.000 abstract 1
206010027599 migraine Diseases 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
229920006395 saturated elastomer Polymers 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
- C07D265/32—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pain & Pain Management (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Rheumatology (AREA)
Hospice & Palliative Care (AREA)
Otolaryngology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

DK95927862T 1994-08-15 1995-08-07 Morpholinderivater og deres anvendelse som terapeutiske midler DK0777659T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB9416427A GB9416427D0 (en)	1994-08-15	1994-08-15	Therapeutic agents
GBGB9509605.3A GB9509605D0 (en)	1995-05-11	1995-05-11	Therapeutic agents
PCT/GB1995/001868 WO1996005181A1 (en)	1994-08-15	1995-08-07	Morpholine derivatives and their use as therapeutic agents

Publications (1)

Publication Number	Publication Date
DK0777659T3 true DK0777659T3 (da)	2001-09-03

Family

ID=26305450

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK95927862T DK0777659T3 (da)	1994-08-15	1995-08-07	Morpholinderivater og deres anvendelse som terapeutiske midler

Country Status (13)

Country	Link
US (1)	US5824678A (da)
EP (1)	EP0777659B1 (da)
JP (1)	JP2002502351A (da)
AT (1)	ATE201866T1 (da)
AU (1)	AU691327B2 (da)
CA (1)	CA2195972A1 (da)
DE (1)	DE69521208T2 (da)
DK (1)	DK0777659T3 (da)
ES (1)	ES2157337T3 (da)
GR (1)	GR3036006T3 (da)
IL (1)	IL114865A (da)
PT (1)	PT777659E (da)
WO (1)	WO1996005181A1 (da)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6117855A (en)	1996-10-07	2000-09-12	Merck Sharp & Dohme Ltd.	Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
US6613765B1 (en)	1996-12-02	2003-09-02	Merck Sharp & Dohme Limited	Use of NK-1 receptor antagonists for treating major depressive disorders
US6114315A (en) *	1996-12-02	2000-09-05	Merck Sharp & Dohme Ltd.	Use of NK-1 receptor antagonists for treating major depressive disorders with anxiety
EP0942732B1 (en) *	1996-12-02	2004-11-17	MERCK SHARP & DOHME LTD.	Use of nk-1 receptor antagonists for treating movement disorders
CA2273807A1 (en) *	1996-12-02	1998-06-11	Merck Sharp & Dohme Limited	Use of nk-1 receptor antagonists for treating schizophrenic disorders
AU731349B2 (en) *	1996-12-02	2001-03-29	Merck Sharp & Dohme Limited	Use of NK-1 receptor antagonists for treating sexual dysfunctions
US5977104A (en) *	1996-12-02	1999-11-02	Merck Sharp & Dohme Ltd.	Use of NK-1 receptor antagonists for treating bipolar disorders
WO1998024438A1 (en) *	1996-12-02	1998-06-11	Merck Sharp & Dohme Limited	Use of nk-1 receptor antagonists for treating major depressive disorders
JP2001504853A (ja) *	1996-12-02	2001-04-10	メルクシヤープエンドドームリミテツド	物質使用障害の治療のためのｎｋ−１受容体拮抗薬の使用
AU736042B2 (en) *	1996-12-02	2001-07-26	Merck Sharp & Dohme Limited	Use of NK-1 receptor antagonists for treating major depressive disorders with anxiety
US6100256A (en) *	1996-12-02	2000-08-08	Merck Sharp & Dohme Ltd.	Use of NK-1 receptors antagonists for treating schizophrenic disorders
EP0942730A1 (en) *	1996-12-02	1999-09-22	MERCK SHARP & DOHME LTD.	Use of nk-1 receptor antagonists for treating bipolar disorders
WO1998024439A1 (en) *	1996-12-02	1998-06-11	Merck Sharp & Dohme Limited	Use of nk-1 receptor antagonists for treating severe anxiety disorders
CA2273853A1 (en) *	1996-12-02	1998-06-11	Merck Sharp & Dohme Limited	Use of nk-1 receptor antagonists for treating cognitive disorders
EP0942729B1 (en) *	1996-12-02	2004-09-01	MERCK SHARP & DOHME LTD.	Use of nk-1 receptor antagonists for treating stress disorders
EP0977572A1 (en) *	1997-04-24	2000-02-09	Merck Sharp & Dohme Ltd.	Use of nk-1 receptor antagonists for treating eating disorders
GB9716463D0 (en) *	1997-08-04	1997-10-08	Merck Sharp & Dohme	Therapeutic agents
GB9716457D0 (en) *	1997-08-04	1997-10-08	Merck Sharp & Dohme	Therapeutic agents
CA2298777A1 (en) *	1997-08-04	1999-02-18	Merck Sharp & Dohme Limited	Use of nk-1 receptor antagonists for treating mania
WO1999007375A1 (en) *	1997-08-04	1999-02-18	Merck Sharp & Dohme Limited	Use of nk-1 receptor antagonists for treating aggressive behaviour disorders
US6156749A (en) *	1997-12-01	2000-12-05	Merck Sharp & Dohme Limited	Use of NK-1 receptor antagonists for treating movement disorders
US6087348A (en) *	1997-12-01	2000-07-11	Merck Sharp & Dohme Ltd.	Use of NK-1 receptor antagonists for treating stress disorders
US6271230B1 (en)	1997-12-01	2001-08-07	Merck Sharp & Dohme Limited	Use of NK-1 receptor antagonists for treating cognitive disorders
AU1230000A (en) *	1998-10-30	2000-05-22	Merck & Co., Inc.	Linear process for the preparation of a morpholine compound
GB9907571D0 (en)	1999-04-06	1999-05-26	Zeneca Ltd	Compounds
WO2001032625A1 (en)	1999-11-03	2001-05-10	Du Pont Pharmaceuticals Company	Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
US7163949B1 (en)	1999-11-03	2007-01-16	Amr Technology, Inc.	4-phenyl substituted tetrahydroisoquinolines and use thereof
US7279547B2 (en) *	2000-02-10	2007-10-09	University Of Connecticut	Insecticidal compounds and methods for selection thereof
AU2001250820A1 (en)	2000-03-13	2001-09-24	Ortho-Mcneil Pharmaceutical, Inc.	Novel cyclohexene derivatives useful as antagonists of the motilin receptor
AU2001247357A1 (en)	2000-03-13	2001-09-24	Ortho-Mcneil Pharmaceutical, Inc.	Novel cyclobutene derivatives useful as antagonists of the motilin receptor
US6392040B2 (en) *	2000-03-13	2002-05-21	Ortho-Mcneil Pharmaceutical, Inc.	Cyclopentene compounds useful as antagonists of the motilin receptor
JP5132864B2 (ja)	2000-07-11	2013-01-30	アルバニーモレキュラーリサーチ，インコーポレイテッド	４−フェニル置換テトラヒドロイソキノリンおよびその使用方法
US20060205724A1 (en) *	2002-05-29	2006-09-14	The Regents Of The University Of California	Antagonizing nk-1 receptors inhibits consumption of substances of abuse
AU2005274927B2 (en)	2004-07-15	2011-11-03	Albany Molecular Research, Inc.	Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
US8362075B2 (en)	2005-05-17	2013-01-29	Merck Sharp & Dohme Corp.	Cyclohexyl sulphones for treatment of cancer
KR101594898B1 (ko)	2005-07-15	2016-02-18	알바니 몰레큘라 리써치, 인크.	아릴- 및 헤테로아릴-치환된 테트라히드로벤자제핀, 및 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도
KR20080048502A (ko)	2005-09-29	2008-06-02	머크 앤드 캄파니 인코포레이티드	멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체
GB0603041D0 (en)	2006-02-15	2006-03-29	Angeletti P Ist Richerche Bio	Therapeutic compounds
US8173629B2 (en)	2006-09-22	2012-05-08	Merck Sharp & Dohme Corp.	Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en)	2006-11-01	2011-09-08	Barbara Brooke Jennings-Spring	Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
EA016079B1 (ru)	2007-01-10	2012-01-30	Институто Ди Ричерке Ди Биолоджиа Молеколаре П. Анджелетти Спа	Амидзамещенные индазолы в качестве ингибиторов поли(adp-рибоза)полимеразы (parp)
JP2010516731A (ja)	2007-01-24	2010-05-20	グラクソグループリミテッド	２−メトキシ−５−（５−トリフルオロメチル−テトラゾール−１−イル）−ベンジル］−（２ｓ−フェニル−ピペリジン−３ｓ−イル）−アミンを含む医薬組成物
JP5319518B2 (ja)	2007-04-02	2013-10-16	Ｍｓｄ株式会社	インドールジオン誘導体
AU2008269154B2 (en)	2007-06-27	2014-06-12	Merck Sharp & Dohme Llc	4-carboxybenzylamino derivatives as histone deacetylase inhibitors
CN102014631A (zh)	2008-03-03	2011-04-13	泰格尔医药科技公司	酪氨酸激酶抑制剂
US9156812B2 (en)	2008-06-04	2015-10-13	Bristol-Myers Squibb Company	Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
WO2010114780A1 (en)	2009-04-01	2010-10-07	Merck Sharp & Dohme Corp.	Inhibitors of akt activity
WO2010132487A1 (en)	2009-05-12	2010-11-18	Bristol-Myers Squibb Company	CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROHPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF
US8802696B2 (en)	2009-05-12	2014-08-12	Albany Molecular Research, Inc.	7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoqu inoli and use thereof
CN102458123A (zh)	2009-05-12	2012-05-16	阿尔巴尼分子研究公司	芳基、杂芳基和杂环取代的四氢异喹啉及其用途
JP5099731B1 (ja)	2009-10-14	2012-12-19	メルク・シャープ・アンド・ドーム・コーポレーション	ｐ５３活性を増大する置換ピペリジン及びその使用
EP2584903B1 (en)	2010-06-24	2018-10-24	Merck Sharp & Dohme Corp.	Novel heterocyclic compounds as erk inhibitors
AU2011285909B2 (en)	2010-08-02	2016-11-10	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
EP2606134B1 (en)	2010-08-17	2019-04-10	Sirna Therapeutics, Inc.	RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US8883801B2 (en)	2010-08-23	2014-11-11	Merck Sharp & Dohme Corp.	Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
EP2613782B1 (en)	2010-09-01	2016-11-02	Merck Sharp & Dohme Corp.	Indazole derivatives useful as erk inhibitors
US9242981B2 (en)	2010-09-16	2016-01-26	Merck Sharp & Dohme Corp.	Fused pyrazole derivatives as novel ERK inhibitors
EP3766975A1 (en)	2010-10-29	2021-01-20	Sirna Therapeutics, Inc.	Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
EP2654748B1 (en)	2010-12-21	2016-07-27	Merck Sharp & Dohme Corp.	Indazole derivatives useful as erk inhibitors
EP2699567A1 (en)	2011-04-21	2014-02-26	Merck Sharp & Dohme Corp.	Insulin-like growth factor-1 receptor inhibitors
WO2013063214A1 (en)	2011-10-27	2013-05-02	Merck Sharp & Dohme Corp.	Novel compounds that are erk inhibitors
EP3358013B1 (en)	2012-05-02	2020-06-24	Sirna Therapeutics, Inc.	Short interfering nucleic acid (sina) compositions
KR20150060724A (ko)	2012-09-28	2015-06-03	머크 샤프 앤드 돔 코포레이션	Erk 억제제인 신규 화합물
DK2925888T3 (da)	2012-11-28	2017-12-18	Merck Sharp & Dohme	Sammensætninger og fremgangsmåder til behandling af cancer
EP2935263B1 (en)	2012-12-20	2018-12-05	Merck Sharp & Dohme Corp.	Substituted imidazopyridines as hdm2 inhibitors
US9540377B2 (en)	2013-01-30	2017-01-10	Merck Sharp & Dohme Corp.	2,6,7,8 substituted purines as HDM2 inhibitors
WO2015034925A1 (en)	2013-09-03	2015-03-12	Moderna Therapeutics, Inc.	Circular polynucleotides
WO2018071283A1 (en)	2016-10-12	2018-04-19	Merck Sharp & Dohme Corp.	Kdm5 inhibitors
US11098059B2 (en)	2017-11-08	2021-08-24	Merck Sharp & Dohme Corp.	PRMT5 inhibitors
WO2019094311A1 (en)	2017-11-08	2019-05-16	Merck Sharp & Dohme Corp.	Prmt5 inhibitors
EP3833668B1 (en)	2018-08-07	2025-03-19	Merck Sharp & Dohme LLC	Prmt5 inhibitors
BR112021002267A8 (pt)	2018-08-07	2023-02-07	Merck Sharp & Dohme	Inibidores de prmt5
EP3833667B1 (en)	2018-08-07	2024-03-13	Merck Sharp & Dohme LLC	Prmt5 inhibitors
CN111004190A (zh) *	2019-11-08	2020-04-14	广州曼翔医药有限公司	一种阿瑞匹坦中间体的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0600952B1 (en) *	1991-08-20	1996-04-17	MERCK SHARP & DOHME LTD.	Azacyclic compounds, processes for their preparation and pharmaceutical compositions containing them
IL106142A (en) *	1992-06-29	1997-03-18	Merck & Co Inc	Morpholine and thiomorpholine tachykinin receptor antagonists, their preparation and pharmaceutical compositions containing them
IL111960A (en) *	1993-12-17	1999-12-22	Merck & Co Inc	Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
DE69434063D1 (de) *	1993-12-29	2004-11-11	Merck Sharp & Dohme	Substituierte Morpholinderivate und ihre Verwendung als therapeutische Mittel

1995
- 1995-08-07 ES ES95927862T patent/ES2157337T3/es not_active Expired - Lifetime
- 1995-08-07 DE DE69521208T patent/DE69521208T2/de not_active Expired - Fee Related
- 1995-08-07 EP EP95927862A patent/EP0777659B1/en not_active Expired - Lifetime
- 1995-08-07 AU AU31855/95A patent/AU691327B2/en not_active Ceased
- 1995-08-07 DK DK95927862T patent/DK0777659T3/da active
- 1995-08-07 WO PCT/GB1995/001868 patent/WO1996005181A1/en not_active Ceased
- 1995-08-07 AT AT95927862T patent/ATE201866T1/de not_active IP Right Cessation
- 1995-08-07 PT PT95927862T patent/PT777659E/pt unknown
- 1995-08-07 US US08/793,186 patent/US5824678A/en not_active Expired - Fee Related
- 1995-08-07 JP JP50710696A patent/JP2002502351A/ja not_active Withdrawn
- 1995-08-07 CA CA002195972A patent/CA2195972A1/en not_active Abandoned
- 1995-08-08 IL IL11486595A patent/IL114865A/xx active IP Right Grant
2001
- 2001-06-07 GR GR20010400305T patent/GR3036006T3/el not_active IP Right Cessation

Also Published As

Publication number	Publication date
ES2157337T3 (es)	2001-08-16
IL114865A0 (en)	1995-12-08
PT777659E (pt)	2001-09-28
EP0777659A1 (en)	1997-06-11
WO1996005181A1 (en)	1996-02-22
ATE201866T1 (de)	2001-06-15
EP0777659B1 (en)	2001-06-06
DE69521208T2 (de)	2001-11-08
DE69521208D1 (de)	2001-07-12
GR3036006T3 (en)	2001-09-28
AU3185595A (en)	1996-03-07
CA2195972A1 (en)	1996-02-22
AU691327B2 (en)	1998-05-14
JP2002502351A (ja)	2002-01-22
US5824678A (en)	1998-10-20
IL114865A (en)	1999-06-20

Publication	Publication Date	Title
GR3036006T3 (en)	2001-09-28	Morpholine derivatives and their use as therapeutic agents
DK1697371T3 (da)	2007-09-17	Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer
DK1697370T3 (da)	2007-09-17	Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer
GB9426103D0 (en)	1995-02-22	Therapeutic agents
ES2159558T3 (es)	2001-10-16	Derivados de guanidina como inhibidores del intercambio na+/h+ en las celulas.
TR200201505T2 (tr)	2003-01-21	Terapötik maddeler olarak pirazolopirimidinler
DK0778834T3 (da)	2000-04-17	Bicykliske, heterocykliske diarylforbindelser som inhibitorer af cyclooxygenase-2
DK0880508T3 (da)	2003-06-30	Quinazolinderivater som VEGF-inhibitorer
NO20014529D0 (no)	2001-09-18	Tetrahydropyranderivater og deres anvendelse som terapautiske midler
ES2143526T3 (es)	2000-05-16	Derivados de amida que tienen actividad antihipercolesterolemica, su preparacion y sus usos terapeuticos.
ES2098947T3 (es)	1997-05-01	Derivados de beta,beta-dimetil-4-piperidinoetanamina como inhibidores de la biosintesis del colesterol.
DK0759026T3 (da)	2000-02-28	Amidderivater og deres terapeutiske anvendelse
JO2231B1 (en)	2004-10-07	Derivatives of Trahydroperan and its use as a therapeutic agent
DK0583271T3 (da)	1999-07-26	Arylmorpholin, fremstilling og anvendelse
PA8471801A1 (es)	2000-09-29	Derivados de higromicina a
NO971261D0 (no)	1997-03-19	Kinoksalin-derivater nyttige innen terapi
SE9603285D0 (sv)	1996-09-10	New compounds
GT200000087A (es)	2001-11-22	Formas polimorfas de un citrato de azabiciclo(2.2.2) octan - 3 - amina y sus composiciones farmaceuticas.
PA8471901A1 (es)	2000-09-29	Derivados de 2"-desoxi higromicina
DK0769945T3 (da)	2003-06-10	Brug af 2-phenyl-3-aroylbenzothiophenderivater til fremstilling af et medikament til behandling af knogler og knoglebrud
SE9603284D0 (sv)	1996-09-10	New compounds
DK0514267T3 (da)	1996-11-11	Hidtil ukendte amidderivater af 1-aminooctahydropyrido(2,1-c)(1,4)oxazin, fremgangsmåder til fremstilling heraf og farmaceutiske midler, som indeholder dem
ECSP993239A (es)	1999-12-23	Derivados de higromicina